Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

RESI San Francisco Asia Pacific Investors Panel

26 Jan

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

During JPM this year, close to 1,000 investment professionals from China gathered in San Francisco, according to unofficial statistics. What hot sectors are they looking for? How can you initiate and maintain a relationship with them? At RESI San Francisco, entrepreneurs and investors filled up the Asia Pacific Investors panel room to learn about the nuts and bolts of cross-border investment.

Moderated by Jimmy Lu, Managing Director, WI Harper Group, the panelists include:

Key takeaway points from the panel:

  • Chinese investors are pushed to look overseas by the following forces: asset price, scarcity of high-quality products, and scarcity of exit in the public market. Many of them are seeking one or more of the following factors from US early stage companies: cutting-edge technologies, large sales potential in their domestic markets, and access to the US market.
  • The Chinese government’s new currency restriction has impacted some transactions and created uncertainty in the future. Dual currency funds (firms that manage domestic RMB and offshore USD funds) are less affected.
  • To engage a Chinese partner, it is key to identify a ‘China hook’ of your product. Large patient population is only one factor. Regulatory process, medical practice, and reimbursement should also be considered.
  • A good partnership can come in different forms: direct investment, licensing, joint venture, M&A, etc. Entrepreneurs should work with experienced investors to form a partnership that is most suitable for their product sector and stage.

Tags: , , , , , , ,

RESI Lands on MaRS Again in 2017

19 Jan

Natasha Eldridge, Marketing Manager – RESI Conference Series, LSN

On April 4, 2017, The Redefining Early Stage Investments (RESI) Conference will be back to Toronto’s MaRS Discovery District, the home of notable life science organizations including JLABS@Toronto, the Ontario Institute for Cancer Research, Synaptive Medical, and LEAGUE. RESI on MaRS will bring together fundraising CEOs and early stage investors from around the globe, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations.

What to expect numbers

Don’t miss the opportunity to attend the 12th RESI conference where you will speak one-on-one with active investors, establish strategic partnerships, learn from the 20 in-depth panels featuring investors across 10 categories (Family Offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more) and find collaborators for licensing and research.

Tags: ,

Crazy Good: Making It Happen @ JPM

19 Jan

By Dennis Ford, Founder & CEO, LSN

 RESI @ JPM has generated feedback from a wide swath of attendees thus far. What LSN has heard has been two quite distinctive words: “Crazy good.” An interesting mantra, and it’s right on.

The overriding response was that the RESI conference is not stale (same old talking heads for decades) or burdened with a sterile-like quality of private white meeting rooms. RESI is not the “quiet car,” and most certainly is not projecting a low energy library-like atmosphere.

On the contrary, when you step into the beehive of RESI and into its palatable energy and buzzing noise, you know it’s different. It’s not only for the elite phase III and commercialization cadre that play in the later stage life science arena.

The RESI conference series is the Wild West of the life science arena, with preclinical and early stage players not looking to be catered to with pomp and circumstance – actually just the opposite. The game is afoot – let’s engage in the hunt for assets! Send forth the hounds, blow the trumpets, let’s make some noise!

Packed into an eclectic 12-story Spanish Colonial-style building built in 1926, RESI attendees were walking up and down tight flights of stairs to get around the crowd, but many seemed to know the drill – it was the third RESI @ JPM event.

And the RESI vibe brings down the walls and barriers and everybody is talking and meeting; it’s just a really open and accepting crowd.

The real win is that the attendees are the who’s who of global early stage investment. Savvy fundraising CEOs are smart enough to figure it out, and booked up to 16 meetings with investors that fit their stage and product – not to mention the additional ad hoc meetings that are the hallmark of the event.

There is a tribe of players, both global early stage investors and startup CEOs, that follow the RESI conference throughout the year. In 2017 there will be 5 RESI events through out North America: San Francisco, Toronto, San Diego, Boston and New York.

RESI is happening and capital is flowing into the drug, device, diagnostic and health IT startups. We hear about the resulting allocations almost every week.

It’s crazy good!

“Know your investors and live your business plan” – BioWorld Highlights RESI @ JPM

19 Jan

By Lucy Parkinson, Director of Research, LSN

As RESI attracts increasing media attention, BioWorld have provided some highlights and analysis on RESI’s content. This roundup focuses on two of RESI’s investor panels: Biotech Angels and Tales From The Road. Between these two sessions, RESI attendees caught a high-level view inside an early stage life science deal from both sides. On one side of the table, angel investors explore how they hunt for deals and work with startups after investment. On the other side, successful CEOs share their stories of finding and vetting investors who are a fit for their companies. You can read more at BioWorld: http://www.bioworld.com/content/know-your-investors-and-live-your-business-plan

Tags: , , , , ,

RESI Innovators Shine in San Francisco – Winners Announced

12 Jan

Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison

Shaoyu 10*10The third RESI San Francisco Conference event, held on January 10th, saw 30 Innovation Challenge finalists competing for the votes of the largest RESI crowd to date.  With 1,000 attendees present, more votes were cast than in any Innovation Challenge to date. Biotech, medical device, diagnostic and digital health companies all competed in the exhibition-style challenge for the top prize.  Selected from over 100 applicants, the 30 finalists included many phenomenal startups.  Here, LSN would like to present the 3 winners.

First Place: Pathcore (Toronto, Canada)

pathcore-500t

Pathcore brings innovation to the crossroads of pathology and computation. By leveraging the power of digital computing and algorithm-based image analysis, digital pathology has the potential to transform healthcare. Pathology is essential to the diagnosis and treatment of cancer and other diseases, as well as the discovery and evaluation of new treatments. Hundreds of millions of dollars are spent on cancer research every year, and Pathcore is focused on providing the tools to accelerate that research and translate it into applied solutions. Pathcore is committed to pathologists and the patients they serve. Our software solutions are designed by pathologists, for pathologists, to enable them to work together, share their knowledge and expertise, and be more accurate, effective, and efficient.

Michael Quigley, VP of Market Research, Life Science Nation | Dan Hosseinzadeh, CEO, Pathcore | George Ayd Assistant Vice President, Medmarc | Stephane Langevin, CCO, Pathcore

Second Place: Myndblue (Cambridge, MA)

myndblue-500

MyndBlue is a digital health/ connected medical device that detects and monitors relapse/recurrence in Major Depressive Disorders and Chronic PTSD. The company is headquartered in Paris and has US office in Cambridge, MA. MyndBlue’s mission is to change the way mental health conditions are diagnosed through technology, data and design – to get patients the right care. Mental health conditions affect around 615 million people worldwide. MyndBlue’s remote monitoring platform allows for a patient to be monitored with a proprietary device to provide information to a clinician before a crisis.

dsc05102

Michael Quigley, VP of Market Research, Life Science Nation | Denis Fompeyrine, PhD Founder & CEO, Myndblue | Nancy Briefs Serial Medical/Digital Health Entrepreneur, Myndblue | George Ayd Assistant Vice President, Medmarc

Third Place: Propep Surgical (Austin, TX)

propep-surgical-500

Sexual dysfunction and urinary incontinence are both common side effects following prostate cancer surgery. Inadvertent nerve injury occurring during the surgery is believed to be one of the primary causes. Using nerve monitoring technology that has been the Standard of Care in multiple surgical procedures for over 20 years, the ProPep® Nerve Monitoring System brings the same instant and accurate information regarding nerve location and function to laparoscopic and robotic prostatectomy surgery for the first time ever. The ProPep® Nerve Monitoring System is the first FDA-cleared real-time nerve monitoring system for laparoscopic & robotic prostatectomy surgery. With over 2500 commercial cases completed this system is proven to help surgeons identify critical non-visible somatic nerves at risk during surgery, thereby allowing the surgeon to make more-informed decisions on how to spare these nerves, potentially minimizing nerve damage.

Thank you to all who competed in the RESI San Francisco Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

Tags: , , , ,

Redefining Early Stage Investments Conference Series – San Francisco 2017 Program Guide Announced

5 Jan

By Nono Hu, Director of Marketing, LSN

LSN is looking forward to hosting the 11th Redefining Early Stage Investments Conference (RESI) during San Francisco’s annual healthcare conference week. At RESI, over 450 investors will be under one roof in search of compelling connections with early stage companies.

LSN would like to present the RESI San Francisco 2017 Program Guide. If you’re planning your day at RESI SF and want to see full lists of the investor panel speakers, RESI Innovation Challenge finalists and service providers you could meet, look no further!

resi-sf-program-guide-wp

Tags: , , ,

2016 Highlights: A Look Back at Next Phase’s Top 10 Articles

29 Dec

By Lucy Parkinson, Director of Research, LSN

Throughout 2016, Next Phase has brought you updates and advice on early stage life science fundraising. This week, we’d like to take a look back at the highlights of the year, from some hard data on drug development funding to tips on marketing and pitching your company. We hope you enjoy this roundup of our top 10 articles of the year. See you in 2017.

  1. Drug Development: What Does It Cost, and Who Has The Capital?
  2. The Journey of the Executive Summary and the PowerPoint Pitch Deck
  3. It’s a Numbers Game: Why Some Folks Book Lots of Partnering Meetings and Others Don’t
  4. Is the Early Stage Opportunistic Investment Strategy Broken?
  5. Top Takeaways for Pitching from the WIB, JLABS, and J&J Innovation Lobster Pot
  6. Short-Term Investors in Long-Long Development: Matching an Investor’s Time Horizon
  7. Calling All Capital Raising CEOs
  8. Corporate Partnerships On The Rise: The Toronto Opportunity
  9. How Massachusetts Wins the War for Global Talent
  10. R&D Tax Credits: A New Non-Dilutive Funding Source For Startups
← Older Entries
Newer Entries →